Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03344965 · ClinicalTrials.gov registry record · Phase 2

Olaparib In Metastatic Breast Cancer

A Phase 2 study of Metastatic Breast Cancer and Invasive Breast Cancer, sponsored by Beth Israel Deaconess Medical Center.

Active
Registry status
Phase 2
Development phase
114
Enrollment target
20
Study locations

NCT03344965 is a Phase 2 study of Metastatic Breast Cancer and Invasive Breast Cancer that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 114 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03344965, a Phase 2 study of Metastatic Breast Cancer and Invasive Breast Cancer, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
114 participants
Enrollment target
20
Study locations

Study Summary

This research study is for patients with metastatic breast cancer. * Metastatic means that the cancer has spread beyond the breast. In addition, through genetic testing of the blood or tumor, an altered gene has been found that suggests the tumor may not be able to repair its genetic material (DNA) when it becomes damaged. * This aspect of the cancer may cause it to be more sensitive - that is, more effectively killed by certain types of drugs such as the study agent being evaluated in this trial, Olaparib. * Olaparib is a type of drug known as a PARP inhibitor. Some types of breast cancer and ovarian cancer share some basic features that make them sensitive to similar treatments. Information from those other research studies suggests that this drug may help to treat metastatic breast cancer. * This study will evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in one of the other genes that function with BRCA1 and BRCA2 to repair damaged DNA .This mutation may have been inherited from a parent, or may have developed only in the tumor. * This study will also evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in BRCA1 or BRCA2 that was acquired by the tumor, but not inherited.

Conditions Studied

Metastatic Breast Cancer Invasive Breast Cancer ATM Gene Mutation PALB2 Gene Mutation BRIP1 Gene Mutation CHEK2 Gene Mutation Somatic Mutation Breast Cancer (BRCA1) Somatic Mutation Breast Cancer (BRCA2) RAD51 Gene Mutation NBN Gene Mutation

Interventions

  • DRUG Olaparib

Study Locations (20)

New York

  • Memorial Sloan Kettering Cancer Center Commack - Commack
  • Memorial Sloan Kettering Cancer Center Westchester - East White Plains
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Cancer Center Nassau - Uniondale

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Brigham and Women's Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

New Jersey

  • Memorial Sloan Kettering Cancer Center Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Cancer Center Monmouth - Middletown
  • Memorial Sloan Kettering Cancer Center Bergen - Montvale

Pennsylvania

  • UPMC Hillman Cancer Center - Erie - Erie
  • University of Pennsylvania - Philadelphia
  • University of Pittsburgh - Pittsburgh

Alabama

  • University of Alabama at Birmingham - Birmingham

California

  • University of California, San Francisco - San Francisco

Illinois

  • University of Chicago - Chicago

Indiana

  • Indiana University - Indianapolis

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2018-04-01
Est. Completion 2026-06-30
Phase Phase 2

Sponsor

Beth Israel Deaconess Medical Center

488 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03344965

The ClinicalTrials.gov registry entry for NCT03344965 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (44% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Olaparib is the first listed.

NCT03344965 reports 20 study locations spanning 11 distinct geographic areas - top geographies include New York, Massachusetts, New Jersey.

Frequently Asked Questions

What is clinical trial NCT03344965 about?

NCT03344965 is a clinical study titled "Olaparib In Metastatic Breast Cancer". This research study is for patients with metastatic breast cancer. * Metastatic means that the cancer has spread beyond the breast. In addition, through genetic testing of the blood or tumor, an altered gene has been found that suggests the tumor may not be able to repair its genetic material (DNA)...

What is the current status of trial NCT03344965?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2018-04-01. Estimated completion is 2026-06-30.

What conditions does trial NCT03344965 study?

This clinical trial studies the following conditions: Metastatic Breast Cancer, Invasive Breast Cancer, ATM Gene Mutation, PALB2 Gene Mutation, BRIP1 Gene Mutation.

What interventions are being tested in trial NCT03344965?

The interventions under investigation include: Olaparib (DRUG).

Who is sponsoring clinical trial NCT03344965?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03344965 being conducted?

This trial has 20 study locations across Alabama, California, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Breast Cancer

All registered trials for this condition

Invasive Breast Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.